Results 281 to 290 of about 131,241 (336)

Human Papillomavirus (HPV) Screening With Universal Access to Vaginal Self‐Testing: Outcomes of an Implementation Trial

open access: yesBJOG: An International Journal of Obstetrics &Gynaecology, Volume 132, Issue 9, Page 1240-1249, August 2025.
ABSTRACT Objective Determine the feasibility of high‐risk human papillomavirus (HPV)‐based cervical screening that included the option of a vaginal swab HPV test (vaginal self‐test). Design Implementation trial. Setting 17 primary care practices. Population or Sample People due for a cervical screening test.
Peter Sykes   +12 more
wiley   +1 more source

Comparative analysis of hysterectomy types and approaches on oncological survival in 2023 FIGO stage II endometrial carcinoma. [PDF]

open access: yesBMC Surg
Sun J   +11 more
europepmc   +1 more source

Gut Microbiota‐Derived Acetate Ameliorates Endometriosis via JAK1/STAT3‐Mediated M1 Macrophage Polarisation

open access: yesMicrobial Biotechnology, Volume 18, Issue 8, August 2025.
This study first reveals acetate as a key gut microbiota metabolite to ameliorate endometriosis (EMs) via JAK1/STAT3‐mediated M1 macrophage polarisation, confirming healthy donor faecal microbiota transplantation (FMT) improves EMs by reshaping microbiota, enhancing acetate, strengthening intestinal barriers and providing a new therapeutic paradigm ...
Yunyun Xu   +9 more
wiley   +1 more source

Unlocking the power of immune checkpoint inhibitors: Targeting YAP1 reduces anti‐PD1 resistance in skin cutaneous melanoma

open access: yesBritish Journal of Pharmacology, Volume 182, Issue 16, Page 3903-3922, August 2025.
Abstract Background and Purpose Immune checkpoint inhibitors, such as anti­PD1, revolutionized melanoma treatment. However, resistance and low response rates remain problems. Our goal was to pinpoint actionable biomarkers of resistance to anti‐PD1 treatment and verify therapeutic effectiveness in vivo.
Szonja Anna Kovács   +13 more
wiley   +1 more source

The HIPPO pathway in gynecological malignancies

open access: yes, 2020
Dong, J.   +4 more
core  

GLP‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials

open access: yesDiabetes, Obesity and Metabolism, Volume 27, Issue 8, Page 4454-4468, August 2025.
Abstract Aims To assess if there is a difference in the oncogenic risk between GLP‐1 RA and comparators in randomized controlled trials. Materials and Methods A meta‐analysis of randomized controlled trials comparing GLP‐1RA to any comparators for diabetes and/or obesity, lasting at least 52 weeks.
Giovanni Antonio Silverii   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy